Abstracts tagged "ANA"

Abstract Number: 0003 • ACR Convergence 2021
Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
Richard Ramonell¹, Matthew Woodruff², Mark Rudolph³, F. Eun-Hyung Lee¹ and Iñaki Sanz⁴, ¹Emory University, Atlanta, GA, ²Emory University, Decatur, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: A massive expanson of plasmablasts or antibody secreting cells (ASC) have been shown in severe patients with SARS-CoV-2 infection and in patients with autoimmune…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1535 • ACR Convergence 2021
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Rebecca Blank¹, Rebecca Haberman², Rochelle Castillo², marie Samanovic³, Parvathy Vasudevanpillai Girija⁴, Paula Rackoff¹, Gary Solomon⁵, Natalie Azar⁶, Pamela Rosenthal⁷, Peter Izmirly⁴, Jonathan Samuels⁸, Brian Golden⁹, Soumya Reddy⁷, Steven B. Abramson⁴, Mark Mulligan³ and Jose Scher⁴, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone School of Medicine, Hartsdale, NY, ⁶NYU Langone, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸NYU Langone, Rye Brook, NY, ⁹NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
Abstract Number: 265 • 2019 ACR/ARP Annual Meeting
Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline
Pamela Anjara ¹, David Liew², Victor Yang ³, Christopher McMaster ² and Russell Buchanan ³, ¹Austin Hospital, Melbourne, Victoria, Australia, ²Austin Health, Melbourne, Victoria, Australia, ³Austin Health, Heidelberg, Victoria, Australia
Background/Purpose: In October 2017, the Australian Rheumatology Association widely promoted a list of five recommendations on low-value practices to general clinicians and patients as part…
Abstract Number: 306 • 2019 ACR/ARP Annual Meeting
Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders
Jihad Ben Gabr¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: The American College of Rheumatology (ACR) established case definitions of 19 specific neuropsychiatric syndromes seen in patients with systemic lupus erythematosus (SLE) (1). Therefore,…
Abstract Number: 308 • 2019 ACR/ARP Annual Meeting
Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays
Konrad Dziamski¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Indirect immunofluorescence (IF) is the recommended initial test for detection of antinuclear antibodies (ANA) by the American College of Rheumatology (Ann Rheum. Dis 69:1420-2),…
Abstract Number: 790 • 2019 ACR/ARP Annual Meeting
Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?
Ovgu Kul Cinar¹, Charlene Foley ², Ali Al-Hussain ³, Kimberly Gilmour ⁴, Matthew Buckland ⁴ and Muthana Al-Obaidi ⁵, ¹Great Ormond Street Hospital, Lonodn, United Kingdom, ²Great Ormond Street Hospital, London, Ireland, ³Great Ormond Street Hospital, London, United Kingdom, ⁴Great Ormond Street Hospital NHS Trust, Camelia Botnar Laboratories, London, United Kingdom, ⁵Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Antinuclear antibodies (ANA) are autoantibodies that recognise cellular antigens found predominantly in the cell nucleus. They are associated with numerous autoimmune diseases such as…
Abstract Number: 791 • 2019 ACR/ARP Annual Meeting
Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis
May Choi¹, Emily Mirizio ², Fernanda Quinteros ³, Katherine Buhler ⁴, Marvin Fritzler ¹ and Kathryn Torok ⁵, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Pittsburgh, Pittsburgh, ³University of Calgary, Calgary, ⁴University of Calgary, Calgary, Canada, ⁵UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: It has become increasingly recognized that extra-cutaneous manifestations, such as musculoskeletal and neurologic involvement, are common in pediatric patients with localized scleroderma (LS). We…
Abstract Number: 11 • 2018 ACR/ARHP Annual Meeting
PAD4-Independent Interaction of ACPA with Nuclear Antigens in Apoptotic Cells and Neutrophil Extracellular Traps (NETs) Defines a Subset of Autoantibodies
Gustaf Wigerblad¹, Katy A. Lloyd¹, Peter Sahlström², Karine Chemin², Johanna Steen², Philip J. Titcombe^2,3, Diana Zhou², Ragnhild Stålesen¹, Bianka Marklein⁴, Elena Ossipova², Johan Rönnelid⁵, Luca Piccoli⁶, Antonio Lanzavecchia⁶, Daniel L. Mueller³, Karl Skriner⁴, Lars Klareskog², Fredrik Wermeling¹, Vivianne Malmström² and Caroline Grönwall⁷, ¹Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ³The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Dept. of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁶Università della Svizzera italiana, Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁷Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) associated anti-citrullinated protein autoantibodies (ACPA) bind a wide range of citrullinated proteins with high cross-reactivity. Recent findings suggest that certain, but…
Abstract Number: 89 • 2018 ACR/ARHP Annual Meeting
Anti-Nuclear Antibodies (ANA) and Air Pollution: Ultrafine Particles and Ozone
Sasha Bernatsky¹, Shouao Wang², May Y Choi³, Scott Weichenthal⁴, Marianne Hatzopoulou⁵, Marvin J. Fritzler⁶ and Audrey Smargiassi⁷, ¹Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada, ⁵Civil and Mineral Engineering, University of Toronto, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Public Health, Université de Montreal, Montreal, QC, Canada
Background/Purpose: Previous studies have suggested links between air pollution (particularly PM2.5) and serum antibodies related to rheumatic diseases. No one has yet examined anti-nuclear antibody…
Abstract Number: 98 • 2018 ACR/ARHP Annual Meeting
Presence of Apoptotic Microparticle Containing Immune Complexes in Asymptomatic ANA+ Individuals Despite the Absence of Inflammation
Carolina Muñoz-Grajales^1,2, Dennisse Bonilla¹, Ariana Karanxha¹, Dario Ferri^1,2, Earl Silverman³, Sindhu Johnson⁴, Arthur Bookman⁵, Zahi Touma^5,6 and Joan E. Wither^1,2,5,7, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Immunology, Department of Immunology, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Department of Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently, little is known about what distinguishes asymptomatic Anti-Nuclear Antibody (ANA) positive individuals (ANA+NS) who will progress to Systemic Lupus Erythematosus (SLE) from those…
Abstract Number: 110 • 2018 ACR/ARHP Annual Meeting
Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
Miles C. Smith¹, Samantha Slight-Webb¹, Susan R. Macwana¹, Judith A. James^2,3 and Joel M. Guthridge¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine & Pathology, Univ. of Oklahoma, Okla, OK
Background/Purpose: One hallmark of the autoimmune disease Systemic lupus erythematosus (SLE) is the presence of antinuclear antibodies (ANAs). While the specificities and levels can indicate…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
Meera Tarazi¹, Carolyn Kushner², Rebecca Gaffney² and Victoria P. Werth³, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Dermatology, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].